Literature DB >> 8067762

Rifampin for therapy of experimental pneumococcal meningitis in rabbits.

R Nau1, K Kaye, M Sachdeva, E R Sande, M G Täuber.   

Abstract

Rifampin at a maximally effective dose was less active than ceftriaxone (both drugs at 10 mg/kg of body weight.h) in a rabbit model of pneumococcal meningitis (delta log10 CFU/ml.h, -0.40 +/- 0.13 versus -0.77 +/- 0.18; P < 0.01). The bactericidal activity of rifampin decreased at concentrations in cerebrospinal fluid greater than those that are clinically achievable, and use of rifampin in combination with ofloxacin had no synergistic or additive effect.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8067762      PMCID： PMC188176          DOI： 10.1128/AAC.38.5.1186

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges.

Authors:  R Nau; H W Prange; S Menck; H Kolenda; K Visser; J K Seydel
Journal:  J Antimicrob Chemother       Date:  1992-06       Impact factor: 5.790

2.  Characteristics and antibiotic therapy of adult meningitis due to penicillin-resistant pneumococci.

Authors:  P F Viladrich; F Gudiol; J Liñares; G Rufi; J Ariza; R Pallares
Journal:  Am J Med       Date:  1988-05       Impact factor: 4.965

3.  THE SLOW RECOVERY OF BACTERIA FROM THE TOXIC EFFECTS OF PENICILLIN.

Authors:  H Eagle; A D Musselman
Journal:  J Bacteriol       Date:  1949-10       Impact factor: 3.490

4.  Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics.

Authors:  J S Bradley; J D Connor
Journal:  Pediatr Infect Dis J       Date:  1991-11       Impact factor: 2.129

5.  Pneumococcal meningitis in a child with a ventriculo-peritoneal shunt.

Authors:  P T O'Keeffe; R Bayston
Journal:  J Infect       Date:  1991-01       Impact factor: 6.072

6.  Response to therapy in an experimental rabbit model of meningitis due to Listeria monocytogenes.

Authors:  W M Scheld; D D Fletcher; F N Fink; M A Sande
Journal:  J Infect Dis       Date:  1979-09       Impact factor: 5.226

7.  Inhibition of cholinergic response by taurine in frog isolated skeletal muscle.

Authors:  A Lehmann; A Hamberger
Journal:  J Pharm Pharmacol       Date:  1984-01       Impact factor: 3.765

Review 8.  The mode of action of 4-quinolones and possible mechanisms of resistance.

Authors:  J T Smith
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

9.  New cephalosporins cefotaxime, cefpimizole, BMY 28142, and HR 810 in experimental pneumococcal meningitis in rabbits.

Authors:  M G Täuber; C J Hackbarth; K G Scott; M G Rusnak; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

10.  Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives.

Authors:  R G Dacey; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191
View more
  18 in total

1.  Synergy between trovafloxacin and ceftriaxone against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro.

Authors:  P Cottagnoud; F Acosta; M Cottagnoud; K Neftel; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

2.  Efficacies of BMS 284756 against penicillin-sensitive, penicillin-resistant, and quinolone-resistant pneumococci in experimental meningitis.

Authors:  Philippe Cottagnoud; Fernando Acosta; Marianne Cottagnoud; Marc Pfister; Martin G Täuber
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall.

Authors:  A Stucki; M Cottagnoud; V Winkelmann; T Schaffner; P Cottagnoud
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

4.  Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level penicillin-resistant Streptococcus pneumoniae.

Authors:  Y S Kim; Q Liu; L L Chow; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 5.  Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae.

Authors:  M M París; O Ramilo; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

Review 6.  Bacterial meningitis in children: critical review of current concepts.

Authors:  Ram Yogev; Judith Guzman-Cottrill
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  Animal models of Streptococcus pneumoniae disease.

Authors:  Damiana Chiavolini; Gianni Pozzi; Susanna Ricci
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

8.  Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis.

Authors:  Philippe Cottagnoud; Marc Pfister; Fernando Acosta; Marianne Cottagnoud; Lukas Flatz; Felix Kühn; Hans-Peter Müller; Armin Stucki
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis.

Authors:  P Cottagnoud; M Cottagnoud; F Acosta; L Flatz; F Kühn; A Stucki; J Entenza
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10-14       Impact factor: 3.267

10.  Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin-resistant pneumococci and prevents selection of levofloxacin-resistant mutants in vitro.

Authors:  F Kühn; M Cottagnoud; F Acosta; L Flatz; J Entenza; P Cottagnoud
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.